CN109628479A - A kind of recombinant expression method of glucagon-like-peptide-1 - Google Patents
A kind of recombinant expression method of glucagon-like-peptide-1 Download PDFInfo
- Publication number
- CN109628479A CN109628479A CN201811587926.XA CN201811587926A CN109628479A CN 109628479 A CN109628479 A CN 109628479A CN 201811587926 A CN201811587926 A CN 201811587926A CN 109628479 A CN109628479 A CN 109628479A
- Authority
- CN
- China
- Prior art keywords
- sumo
- rolglp
- fusion
- fusion gene
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 27
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title claims abstract description 24
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 title claims abstract description 9
- 238000003259 recombinant expression Methods 0.000 title claims abstract description 9
- 102100040918 Pro-glucagon Human genes 0.000 title description 19
- 230000004927 fusion Effects 0.000 claims abstract description 43
- 108010043401 Small Ubiquitin-Related Modifier Proteins Proteins 0.000 claims abstract description 30
- 230000014509 gene expression Effects 0.000 claims abstract description 30
- 102000002669 Small Ubiquitin-Related Modifier Proteins Human genes 0.000 claims abstract description 28
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 20
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 12
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 230000001939 inductive effect Effects 0.000 claims abstract description 7
- 238000005119 centrifugation Methods 0.000 claims abstract description 5
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims abstract 3
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 241000588724 Escherichia coli Species 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 8
- 239000013599 cloning vector Substances 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 101000708016 Caenorhabditis elegans Sentrin-specific protease Proteins 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims 4
- 241000024188 Andala Species 0.000 claims 1
- 102000004860 Dipeptidases Human genes 0.000 claims 1
- 108090001081 Dipeptidases Proteins 0.000 claims 1
- 102000004533 Endonucleases Human genes 0.000 claims 1
- 108010042407 Endonucleases Proteins 0.000 claims 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 claims 1
- 102000051619 SUMO-1 Human genes 0.000 claims 1
- 108700038981 SUMO-1 Proteins 0.000 claims 1
- 229920002684 Sepharose Polymers 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 238000010367 cloning Methods 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
- 230000029087 digestion Effects 0.000 abstract description 15
- 229920001184 polypeptide Polymers 0.000 abstract description 7
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 7
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- RKGLLHCSSVJTAN-YYICOITRSA-N glucagen Chemical compound Cl.C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 RKGLLHCSSVJTAN-YYICOITRSA-N 0.000 abstract description 3
- 229940095886 glucagen Drugs 0.000 abstract description 3
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 13
- 230000009182 swimming Effects 0.000 description 13
- 206010012601 diabetes mellitus Diseases 0.000 description 9
- 238000000746 purification Methods 0.000 description 8
- 238000001502 gel electrophoresis Methods 0.000 description 7
- 238000004925 denaturation Methods 0.000 description 6
- 230000036425 denaturation Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000006698 induction Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 4
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 102000044159 Ubiquitin Human genes 0.000 description 3
- 108090000848 Ubiquitin Proteins 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 238000001712 DNA sequencing Methods 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 102100025292 Stress-induced-phosphoprotein 1 Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000002525 ultrasonication Methods 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
Abstract
A kind of recombinant expression method of glucagon-like-peptide-1 includes the following steps the fusion SUMO-rolGLP-1 for 1) constructing a kind of DNA sequence dna containing coding small ubiquitin-related modifier proteins and the DNA sequence dna for encoding Gluca Gen sample polypeptide -1；2) colibacillus engineering of a kind of coli expression carrier including fusion SUMO-rolGLP-1 and high expression fusion SUMO-rolGLP-1 is constructed；3) inducing expression is carried out to colibacillus engineering strain, obtains fusion protein；4) fusion protein is isolated and purified using nickel-Ago-Gel；5) albumen by step 4) purifying uses protease digestion, obtains the mixture of SUMO and rolGLP-1 albumen；6) after the mixture that step 5) obtains is using Ni-FF absorption SUMO albumen, rolGLP-1 albumen is collected by centrifugation in super filter tube.
Description
Technical field
The present invention relates to the recombinant expression methods of glucagon-like-peptide-1.
Background technique
According to the pathogenesis of diabetes, three types can be largely divided into: type 1 diabetes --- also known as insulin according to
Relying property diabetes, diabetes B --- also known as adult-onset diabetes, gestational diabetes mellitus, wherein diabetes B is most normal
See, accounts for about the ninety percent of whole diabetics.
In the enteron aisle of mammal, there is the pancreas hyperglycemia of about 3kD that L cell is secreted under the stimulation absorbed nourishment a kind of
Plain sample peptide -1 (GLP-1) has the function of promoting insulin secretion.GLP-1 by with throughout in pancreas, brain, gastrointestinal tract, the heart
GLP-1 receptor (GLP-1R) in the tissue such as dirty, lung is associated and shows the physiological action of blood glucose-control, but GLP-1R is in pancreas
In abundance to be much higher than its hetero-organization [3].GLP-1R secretion determines that GLP-1 is complicated and extensive in the characteristics of multiple tissue
Physiological function.In terms of physiology, GLP-1 major function includes: 1. to stimulate insulin secretion.GLP-1 is concentration of glucose
Dependent form hormone can just play when blood sugar concentration is higher than normal level and promote insulin secretion effect, mortality is not occurring
Blood sugar reducing function is played under the premise of the risk of hypoglycemia.2. GLP-1 can contain glucagon secretion in conjunction with alpha Cell of islet
[8].3. inhibiting β Apoptosis.Farilla et al. discovery, GLP-1 can stablize the three-dimensional structure of pancreas islet, and islet cells is inhibited to subtract
It is few；Hui [10] et al. discovery, GLP-1 can inhibit apoptotic proteins active, promote the expression of anti-apoptotic proteins, inhibit β to play
The effect of Apoptosis.4. GLP-1 can promote to transcribe insulin gene, it is proliferated islet cells and promotes pancreatic stem cell differentiation
β cell is proliferated for β cell.5. inhibiting bowel movement and gastric emptying, appetite is reduced, promotes liver, fat, musculature glycogen
Synthesis.
China is most one of the country of diabetes B number of patients, and disease incidence is up to 11.6%, and diabetes have become prestige
The serious public health problem of people's the level of physical diathesis is coerced, it is heavy that annual health care costs are brought to diabetic and country
The burden of weight, it is extremely urgent to develop the new treatment diabetes medicament having no toxic side effect.Since GLP-1 makees without gastrointestinal tract pair
With it is anti-mainly to develop three classes GLP-1 class in the market for protection beta Cell of islet, the safe hypoglycemic effect for promoting insulin secretion
Diabetes medicament: DDP-4 inhibitor, GLP-1R agonist, GLP-1 analog have shown good application prospect at this stage,
And part has been used for clinic.
Small ubiquitin-related modifier proteins (SUMO) are a kind of height for being distributed widely in about 15kD in various eukaryotic cells
Conservative little albumen, its structure and reactive mode is similar to ubiquitin, but has the function of different.SUMOization modification and ubiquitin
The common ground for changing modification is lysine residue that binding site is destination protein, cohesive process be required to activating enzymes, desmoenzyme,
The participation of ligase, but the activating enzymes of ubiquitination and ligase huge number, and both enzymes of SUMOization modification only have
One kind, this is likely to be the reason of protein stability after SUMO is modified significantly improves.Stability in addition to improving albumen,
SUMO can also inhibit protein degradation because the binding site of SUMO and ubiquitin is lysine, the two can it is emulative with
Binding Capacity, to play antiprotease hydrolysis function.In addition, SUMOization modification can also keep the steady of antigen-4 fusion protein gene group
It is qualitative, it folds polypeptide normally, improves the solubility of fusion protein.
Glucagon-like-peptide-1 is easily degraded as a kind of small molecular protein and is difficult to purify, and how to improve existing
GLP-1 recombinant expression method improves its yield and simplifies purification step as urgent problem to be solved in the prior art.
Summary of the invention
To solve aforementioned technical problem, the sequence of GLP-1 is recombinated to obtain rolGLP-1 by the present invention, then by SUMO with
It, is then cloned on the pET 22b expression vector in escherichia expression system, constructs a weight by rolGLP-1 fusion
Group SUMO-rolGLP-1 prokaryotic expression carrier, makes it in E. coli, isolates and purifies SUMO- using Ni-FF
RolGLP-1, then the SUMO-rolGLP-1 albumen after SUMO protease digestion is adsorbed into SUMO albumen, super filter tube using Ni-FF
RolGLP-1 is collected by centrifugation.
The technical solution adopted by the present invention is to provide a kind of recombinant expression method of glucagon-like-peptide-1, feature
It is that the described method comprises the following steps
1) it constructs a kind of containing the DNA sequence dna for encoding small ubiquitin-related modifier proteins (SUMO) and coding Gluca Gen
The fusion SUMO-rolGLP-1 of the DNA sequence dna of sample polypeptide -1 (rolGLP-1)；The fusion SUMO-rolGLP-1
In, in the DNA sequence dna of the coding Gluca Gen sample polypeptide -1 (rolGLP-1), dipeptidyl peptidase Ⅳ and trypsase are known
Other site has been removed, and the 8th Ala is replaced by Ser, and the 26th and 34 Lys is replaced by Gln and Asp respectively；It is described to melt
The DNA sequence dna of gene SUMO-rolGLP-1 is closed as shown in sequence 1.
In the step 1), the method for obtaining the fusion SUMO-rolGLP-1 is will by the method for recombinant PCR
The DNA sequence dna for encoding SUMO, which merge with the DNA sequence dna of coding rolGLP-1, obtains the fusion SUMO-rolGLP-
1；Detailed process includes: to be merged SUMO gene with rolGLP-1 gene by the method for recombinant PCR, by SUMO-GLP-1
Fusion gene cloning obtains pMD18T-Simple-SUMO-GLP-1, the carrier is i.e. such as sequence 1 to pMD18T-Simple carrier
Shown in fusion SUMO-GLP-1 gene order.
2) a kind of coli expression carrier pNK-EC-SUMO- including fusion SUMO-rolGLP-1 is constructed
The colibacillus engineering NK-SUMO-rolGLP-1 of rolGLP-1 and high expression fusion SUMO-rolGLP-1, it is specific
Step includes
2.1) the fusion SUMO-rolGLP-1 that step 1) obtains is cloned into pMD18T-Simple carrier, is wrapped
The cloning vector pMD18T-Simple-SUMO-rolGLP-1 of the SUMO-rolGLP-1 containing fusion；
2.2) coli expression carrier pNK-EC-SUMO-rolGLP-1, the structure of the coli expression carrier are provided
It is as follows to build process:
The fusion SUMO- in cloning vector pMD18T-Simple-SUMO-rolGLP-1 that step 2.1) is obtained
RolGLP-1 carries out digestion with BamH I and Nde I restriction endonuclease, and digestion fusion SUMO-rolGLP-1 after the recovery is connected into
PET-22b (+) carrier, building obtain coli expression carrier pNK-EC-SUMO-rolGLP-1；
2.3) Escherichia coli are converted with the coli expression carrier pNK-EC-SUMO-rolGLP-1 that step 2.2) obtains
BL21 (DE3) screens the bacterial strain of wherein highly expressed fusion SUMO-rolGLP-1 as colibacillus engineering NK-
SUMO-rolGLP-1。
3) inducing expression is carried out to colibacillus engineering strain NK-SUMO-rolGLP-1, obtains SUMO-rolGLP-1 and melts
Hop protein.
4) nickel-Ago-Gel (Ni-FF) purification procedures 3 are used) obtained SUMO-rolGLP-1 fusion protein,
5) the SUMO-rolGLP-1 albumen by step 4) purifying uses SUMO protease digestion SUMO-rolGLP-1, obtains
The mixture of SUMO and rolGLP-1 polypeptide
6) after the mixture for the SUMO and rolGLP-1 polypeptide that step 5) obtains is using Ni-FF absorption SUMO albumen, ultrafiltration
RolGLP-1 albumen is collected by centrifugation in pipe.
A kind of recombinant expression method of glucagon-like-peptide-1 provided by the invention is obtained with gene manipulation techniques
SUMO-rolGLP-1 fusion is cloned into coli expression carrier and obtains pNK-EC-SUMO-rolGLP-1, and
Colibacillus engineering strain NK-SUMO-rolGLP- is constructed based on coli expression carrier pNK-EC-SUMO-rolGLP-1
1, by the inducing expression to colibacillus engineering strain, expression product is isolated and purified using affinity chromatography, be can get
SUMO-rolGLP-1 albumen is carried out digestion using SUMO protease, produced after digestion by high-purity SUMO-rolGLP-1 albumen
Object is using the rolGLP-1 albumen that can be obtained high-purity after purification.
Detailed description of the invention
Fig. 1 is coli expression carrier pNK-EC-SUMO-rolGLP-1 described in step 2.2) in specific embodiment
Building process schematic diagram；
Fig. 2 is the gel for the fusion SUMO-rolGLP-1 that step 1) is obtained by recombinant PCR in specific embodiment
Electrophoretogram；
Fig. 3 carries out NK-SUMO-rolGLP-1 with colibacillus engineering strain for step 3) in specific embodiment and induces table
Up to the inducing expression and soluble analysis gel electrophoresis figure for obtaining SUMO-rolGLP-1 fusion protein.
Fig. 4 carries out NK-SUMO-rolGLP-1 with colibacillus engineering strain for step 3) in specific embodiment and induces table
Up to the SDS-PAGE electrophoresis detection and Western blot testing result figure for obtaining SUMO-rolGLP-1 fusion protein
Fig. 5 is to purify SUMO-rolGLP-1 albumen and digestion products in step 4) and step 5) in specific embodiment
Gel electrophoresis figure；
Fig. 6 is the gel electrophoresis figure of the rolGLP-1 albumen of step 6) after purification in specific embodiment.
Specific embodiment
1) is melted the DNA sequence dna of the DNA sequence dna for encoding SUMO and coding rolGLP-1 by the method for recombinant PCR
It closes and obtains the fusion SUMO-rolGLP-1.
PCR primer used in the recombinant PCR is the DNA sequencing fragment and coding rolGLP-1 according to coding SUMO
DNA sequencing fragment design, comprising:
Primer 1, sequence are SEQ ID NO:2
Primer 2, sequence are SEQ ID NO:3
Primer 3, sequence are SEQ ID NO:4
Primer 4, sequence are SEQ ID NO:5
The specific method of the recombinant PCR be using primer 1 and primer 2 as upstream and downstream, be to encode the DNA sequence dna of SUMO
Template expands SUMO-Linker gene, PCR reaction condition are as follows: 94 DEG C of initial denaturation 5min, 94 DEG C of denaturation 30s, 60 DEG C are annealed
1min 72 DEG C, extends 1min, recycles 20 times, 72 DEG C of extension 5min；
It is expanded using primer 3 and primer 4 as upstream and downstream primer using the DNA sequence dna for encoding rolGLP-1 as template
Linker-rolGLP-1 gene, PCR reaction condition are 94 DEG C of initial denaturation 5min, 94 DEG C of denaturation 30s, 60 DEG C of annealing 1min, 72 DEG C
Extend 1min, recycles 20 times, 72 DEG C re-extend 5min.
It is respectively upstream and downstream primer with primer 1 and primer 4, with SUMO-Linker gene and Linker-rolGLP-1 base
Because template obtains SUMO-rolGLP-1 gene, PCR reaction condition: 94 DEG C of initial denaturation 5min, 94 DEG C of denaturation 30s, 60 DEG C are annealed
1min, 72 DEG C of extension 1min are recycled 20 times, and 72 DEG C re-extend 5min.Fusion SUMO-rolGLP-1 is obtained, sequence is such as
Shown in sequence 1, the gel electrophoresis figure of amplified production is as shown in Fig. 2, swimming lane 1 is 100bp DNA Ladder Marker, swimming in figure
Road 2~5 is the fusion SUMO-rolGLP-1 product that recombinant PCR expands.
The DNA sequence dna of the SUMO-Linker gene is as shown in SEQ ID NO:6, the Linker-rolGLP-1 gene
DNA sequence dna as shown in SEQ ID NO:7.
2) a kind of coli expression carrier pNK-EC-SUMO- including fusion SUMO-rolGLP-1 is constructed
The colibacillus engineering NK-SUMO-rolGLP-1 of rolGLP-1 and high expression fusion SUMO-rolGLP-1, it is specific
Step includes
2.1) the fusion SUMO-rolGLP-1 that step 1) obtains is cloned into pMD18T-Simple carrier, is wrapped
The cloning vector pMD18T-Simple-SUMO-rolGLP-1 of the SUMO-rolGLP-1 containing fusion；
2.2) coli expression carrier pNK-EC-SUMO-rolGLP-1, the structure of the coli expression carrier are provided
It is as follows to build process:
The fusion SUMO- in cloning vector pMD18T-Simple-SUMO-rolGLP-1 that step 2.1) is obtained
RolGLP-1 carries out digestion with BamH I and Nde I restriction endonuclease, and digestion fusion SUMO-rolGLP-1 after the recovery is connected into
PET-22b (+) carrier, building obtain coli expression carrier pNK-EC-SUMO-rolGLP-1；The Bacillus coli expression
Carrier pNK-EC-SUMO-rolGLP-1 building process schematic diagram is as shown in Figure 1.
2.3) with step 2.2) obtain through correct coli expression carrier pNK-EC-SUMO-rolGLP-1 is sequenced
It converts e. coli bl21 (DE3), screens the bacterial strain of wherein highly expressed fusion SUMO-rolGLP-1 as Escherichia coli
Engineering bacteria NK-SUMO-rolGLP-1.
3) inducing expression is carried out to colibacillus engineering strain NK-SUMO-rolGLP-1, obtains SUMO-rolGLP-1 and melts
Hop protein
By colibacillus engineering strain NK-SUMO-rolGLP-1, in 37 DEG C, 180rpm shaking flask culture to OD600 be 0.6-
Final concentration of 1mmol/L inducer IPTG is added when 0.8, and 4h is induced under the conditions of 37 DEG C, centrifuging and taking thallus carries out ultrasonication,
Extract proteins, which carry out 15%SDS-PAGE electrophoresis detection, proves successful expression SUMO-GLP-1 fusion protein.Western blot
(immunoblotting) the result shows that, the antibody of SUMO-rolGLP-1 fusion protein and GLP-1 specificity can carry out specificity
In conjunction with.For the gel electrophoresis figure of inducing expression and soluble analysis as shown in figure 3, in figure, M is albumen marker, and swimming lane 1 is the positive
It compares (whole cell after induction), swimming lane 2 is to precipitate after induction is broken, and swimming lane 3 is supernatant after induction is broken, and swimming lane 4 is negative right
According to (before induction).The SDS-PAGE electrophoresis detection and Western blot of SUMO-rolGLP-1 fusion protein are detected such as Fig. 4 institute
Show, swimming lane M in Fig. 4 (A): standard Marker；Swimming lane 1: before induction；Swimming lane 2,3: supernatant after ultrasonication, Fig. 4 (B) are SUMO-
The Wester-blot result of rolGLP-1 fusion protein.
4) SUMO-rolGLP-1 is isolated and purified using Ni-FF
Supernatant after step 3) ultrasonic treatment is subjected to affinity chromatography (Ni-FF chromatographic column) purification process, is obtained high-purity
The SUMO-rolGLP-1 albumen of degree.It is concentrated using the super filter tube of 10kDa, desalination.Purifying
5) SUMO protease digestion SUMO-rolGLP-1 albumen is used, the mixture of SUMO and rolGLP-1 polypeptide is obtained
Digestion will be carried out with SUMO enzyme by the SUMO-rolGLP-1 albumen of concentration desalination in step 4), obtains SUMO and rolGLP-1
The mixture of albumen.The gel electrophoresis figure of SUMO-rolGLP-1 and digestion products are purified as shown in figure 5, M is ultra-low molecular in figure
Measure albumen marker, swimming lane 1SUMO-rolGLP-1 albumen；Swimming lane 2-6 is product after SUMO-rolGLP-1 proteolytic cleavage.
6) after by digestion products using Ni-FF absorption SUMO albumen, rolGLP-1 albumen is collected by centrifugation by step in super filter tube
5) mixture for the SUMO and rolGLP-1 albumen that digestion obtains carries out affinity chromatography (Ni-FF chromatographic column) purification process, SUMO
Albumen can be adsorbed by Ni-FF, then be centrifuged with the super filter tube of 3kDa, and collecting filtrate is rolGLP-1 albumen, the purifying
The liquid chromatogram content of rolGLP-1 albumen afterwards is 91.81%, gel electrophoresis figure such as Fig. 6 of rolGLP-1 albumen after purification
Shown, in figure, M is Ultra-low molecular weight albumen marker, and swimming lane 1, swimming lane 2 are rolGLP-1 after purification.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811587926.XA CN109628479A (en) | 2018-12-25 | 2018-12-25 | A kind of recombinant expression method of glucagon-like-peptide-1 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811587926.XA CN109628479A (en) | 2018-12-25 | 2018-12-25 | A kind of recombinant expression method of glucagon-like-peptide-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109628479A true CN109628479A (en) | 2019-04-16 |
Family
ID=66077310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811587926.XA Pending CN109628479A (en) | 2018-12-25 | 2018-12-25 | A kind of recombinant expression method of glucagon-like-peptide-1 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109628479A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021135765A1 (en) * | 2019-12-31 | 2021-07-08 | 翰宇药业（武汉）有限公司 | Salt conversion method for glp-1 analogue |
| WO2022032991A1 (en) * | 2020-08-10 | 2022-02-17 | 安徽新熙盟生物科技有限公司 | Method for efficiently expressing and purifying mannanase, homologues thereof and glp-1 recombinant fusion protein, and use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030086918A1 (en) * | 2001-05-04 | 2003-05-08 | Lima Christopher D. | Rapidly cleavable sumo fusion protein expression system for difficult to express proteins |
| CN102839185A (en) * | 2011-06-21 | 2012-12-26 | 南开大学 | Construction method and application technology of rolGLP-HV engineering bacterium |
| CN106434717A (en) * | 2015-11-05 | 2017-02-22 | 杭州九源基因工程有限公司 | Method for biosynthesis preparation of human GLP-1 polypeptide or analogue thereof |
-
2018
- 2018-12-25 CN CN201811587926.XA patent/CN109628479A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030086918A1 (en) * | 2001-05-04 | 2003-05-08 | Lima Christopher D. | Rapidly cleavable sumo fusion protein expression system for difficult to express proteins |
| CN102839185A (en) * | 2011-06-21 | 2012-12-26 | 南开大学 | Construction method and application technology of rolGLP-HV engineering bacterium |
| CN106434717A (en) * | 2015-11-05 | 2017-02-22 | 杭州九源基因工程有限公司 | Method for biosynthesis preparation of human GLP-1 polypeptide or analogue thereof |
Non-Patent Citations (1)
| Title |
|---|
| EVA BOSSE-DOENECKE ET AL.: "High yield production of recombinant native and modified peptides exemplified by ligands for G-protein coupled receptors", 《PROTEIN EXPRESSION AND PURIFICATION》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021135765A1 (en) * | 2019-12-31 | 2021-07-08 | 翰宇药业（武汉）有限公司 | Salt conversion method for glp-1 analogue |
| CN113121675A (en) * | 2019-12-31 | 2021-07-16 | 翰宇药业（武汉）有限公司 | Salt conversion method of GLP-1 analogue |
| WO2022032991A1 (en) * | 2020-08-10 | 2022-02-17 | 安徽新熙盟生物科技有限公司 | Method for efficiently expressing and purifying mannanase, homologues thereof and glp-1 recombinant fusion protein, and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110128552B (en) | Fusion protein and method for preparing liraglutide intermediate polypeptide by using same | |
| CN111793126A (en) | Preparation method of GLP-1 analogue polypeptide and application thereof in type II diabetes | |
| CN100564517C (en) | A kind of anti-glioma peptide of scorpion and its production and application | |
| CN110305223A (en) | The method that recombination fused in tandem albumen prepares target polypeptides | |
| CN107033234B (en) | Acylated glp-1 derivatives | |
| CN113278060B (en) | GLP-1/glucagon dual agonist fusion proteins | |
| CN106046176B (en) | A kind of high active long-acting hypoglycemic fusion protein and preparation method thereof and medical usage | |
| CN109628479A (en) | A kind of recombinant expression method of glucagon-like-peptide-1 | |
| CN113265007A (en) | Fusion protein for treating metabolic diseases and preparation method and application thereof | |
| CN101775072B (en) | Glial cell line-Derived Neurotrophic Factor (GDNF) fusing penetrating peptides | |
| CN1982336B (en) | A kind of human glucagon-like peptide-1 derivative and its preparation and application | |
| CN113583142A (en) | Double-target fusion protein, coding gene, vector or host cell and application and expression and purification method thereof | |
| CN101220088B (en) | Amalgamation protein of human glucagons-like peptide-1 and uses thereof | |
| CN100392070C (en) | Genetically engineered bacteria expressing human glucagon-like peptide-1 and its construction method and application | |
| CN111217915B (en) | GLP-1 analogue Fc fusion polypeptide and application thereof | |
| CN106279430B (en) | Analog fusions of Exendin 4 and its production and use | |
| CN106390100B (en) | Application, method and fusion protein complex of a polypeptide complex as a GLP-1 drug carrier | |
| CN102660491A (en) | Gene engineering bacteria high-efficiently expressing recombined human glucagon-like peptide-1 (1-37) and construction method and application thereof | |
| CN102585015B (en) | Fusion protein containing glicetin-1 as well as preparation method and application | |
| CN106146668A (en) | The preparation method and its usage of long-acting interleukin II 2 | |
| EP3875465A1 (en) | Method for modification of polypetide and uses | |
| CN102732549B (en) | Preparation method of recombinant insulin-like growth factor-I (IGF-I) | |
| CN102796192A (en) | Human glucagon-like peptide-1 analogue | |
| CN102260346B (en) | Exendin-4 analog | |
| CN110092825A (en) | A method of Liraglutide intermediate polypeptide is prepared using genetic recombination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190416 |
|
| RJ01 | Rejection of invention patent application after publication |